Mick Correll is the president of Genospace, the leading information platform for applied precision medicine and the precision medicine platform of Sarah Cannon. In his role, he focuses on company strategy, business development and team leadership.
As co-founder and CEO, Mick led Genospace to a successful merger with Sarah Cannon, the Cancer Institute of HCA Healthcare, in January of 2017. Over his career, Mick has held leadership positions in academia and industry and has developed informatics solutions for pharma/biotech, ag bio, and academic, government and community healthcare providers. Prior to launching Genospace, he was the associate director of the Center for Cancer Computational Biology at the Dana-Farber Cancer Institute. Mick began his career at Lion Bioscience Research Inc. and UK-based informatics provider InforSense. Mick earned a Bachelor of Science in computer science and Bachelor of Arts in molecular biology from the University of Colorado at Boulder.